Evogene Ltd. - Ordinary Shares (EVGN): Price and Financial Metrics


Evogene Ltd. - Ordinary Shares (EVGN)

Today's Latest Price: $1.22 USD

0.01 (0.59%)

Updated Jun 5 3:15pm

Add EVGN to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 27 in Agriculture

See all "A" rated Strong Buy stocks

EVGN Stock Summary

  • The capital turnover (annual revenue relative to shareholder's equity) for EVGN is 0.02 -- better than merely 9.11% of US stocks.
  • EVGN's price/sales ratio is 41.35; that's higher than the P/S ratio of 95.91% of US stocks.
  • As for revenue growth, note that EVGN's revenue has grown -93.23% over the past 12 months; that beats the revenue growth of merely 0.94% of US companies in our set.
  • If you're looking for stocks that are quantitatively similar to Evogene Ltd, a group of peers worth examining would be ORMP, SYBX, MGEN, CDTX, and CLDX.
  • EVGN's SEC filings can be seen here. And to visit Evogene Ltd's official web site, go to www.evogene.com.
EVGN Daily Price Range
EVGN 52-Week Price Range

EVGN Stock Price Chart More Charts


EVGN Price/Volume Stats

Current price $1.22 52-week high $1.83
Prev. close $1.21 52-week low $0.75
Day low $1.16 Volume 57,418
Day high $1.23 Avg. volume 28,302
50-day MA $1.09 Dividend yield N/A
200-day MA $1.38 Market Cap 31.31M

Evogene Ltd. - Ordinary Shares (EVGN) Company Bio


Evogene Ltd. operates as a plant genomics company that uses a technology infrastructure to enhance seed traits underlying crop productivity. The company was founded in 1999 and is based in Rehovot, Israel.


EVGN Latest News Stream


Event/TimeNews Detail
Loading, please wait...

EVGN Latest Social Stream


Loading social stream, please wait...

View Full EVGN Social Stream

Latest EVGN News From Around the Web

Below are the latest news stories about Evogene Ltd that investors may wish to consider to help them evaluate EVGN as an investment opportunity.

Evogene to Participate in CRISPR-IL Consortium to Provide End-to-End Artificial Intelligence System for Genome-Editing

Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN.TA), a leading computational biology company targeting to revolutionize life-science product development across several market segments, announced today its participation in the CRISPR-IL consortium. The goal is to develop "Go-Genome", an artificial intelligence (AI) based, end-to-end system for genome-editing to be used in multi-species for pharma, agriculture, and aquaculture. Evogene's CSO, Dr. Eyal Emmanuel will serve as the Chairman of the consortium.

Yahoo | June 3, 2020

Evogene Reports First Quarter 2020 Financial Results

REHOVOT, Israel, May 26, 2020 /PRNewswire/ -- Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN.TA), a leading computational biology company targeting to revolutionize life-science product development across several market segments, announced today its financial results for the first quarter, ended…

PR Newswire | May 26, 2020

Evogene Posts Q1 Results, Suffers 67% YoY Revenue Decline

Biotechnology company Evogene Ltd. (NASDAQ: EVGN ) released Tuesday its financial results for the first quarter of 2020. The Israel-based company, which is oriented toward improving crop quality and productivity, saw the quarter's year-over-year revenue decrease by roughly 67%, from $300,000 in 2019 to $100,000. The first quarter of 2020 showed a significant decline compared to the same period in the last year. Evogene has been struggling for months as its fourth quarter financial update reported downturns as well. Here's a breakdown of what the earnings report for the first quarter showed: Gross profit was $36 000, compared to a gross … Full story available on Benzinga.com

Benzinga Feeds | May 26, 2020

Evogene Launches Its New Branding to Reflect the Company's Expanded Vision and New Business Model

Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN.TA), a leading computational biology company targeting to revolutionize life-science product development across several market segments, announces today its rebranding. The new corporate identity reflects the company's expanded vision and new business model.

Yahoo | May 20, 2020

Evogene Financial Results and Earnings Announcement Schedule for the First Quarter of 2020

REHOVOT, Israel, May 7, 2020 /PRNewswire/ -- Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN.TA), a leading biotechnology company aiming to revolutionize the development of novel products for life-science based industries by utilizing cutting edge computational biology technologies, announces…

PR Newswire | May 7, 2020

Read More 'EVGN' Stories Here

EVGN Price Returns

1-mo 8.93%
3-mo 1.59%
6-mo -5.95%
1-year -19.21%
3-year -76.31%
5-year -87.81%
YTD -19.74%
2019 -23.23%
2018 -35.50%
2017 -39.80%
2016 -36.65%
2015 -12.60%

Continue Researching EVGN

Want to see what other sources are saying about Evogene Ltd's financials and stock price? Try the links below:

Evogene Ltd (EVGN) Stock Price | Nasdaq
Evogene Ltd (EVGN) Stock Quote, History and News - Yahoo Finance
Evogene Ltd (EVGN) Stock Price and Basic Information | MarketWatch


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.8513 seconds.